Operations open at GSK spinoff LimmaTech Biologics
The company was established in May 2015 after GSK acquired GlycoVaxyn, a clinical stage biopharmaceutical firm specializing in developing and researching next-generation bioconjugate vaccines. The company used its proprietary technology to biologically synthesize glyco-conjugate antigens.
After the acquisition, GSK requested that the management team from GlycoVaxyn make a new company called LimmaTech Biologics, where the operational research business from GlycoVaxyn has been transferred.
“We are extremely pleased with this research and development agreement between GSK and LimmaTech Biologics and this very innovative business relationship,” Managing Director Veronica Gambillara Fonck said. “This is a fantastic opportunity for our research organization to contribute to the development of an exciting new generation of vaccines. Whilst we aim to retain the agility and innovativeness of a small biotech company in LimmaTech, we will benefit tremendously from the support, expertise and sheer development power that GSK brings.”
Technically, LimmaTech Biologics is not owned by GSK. Rather, GSK and LimmaTech Biologics have made a research agreement that will last for five years. The agreement enables LimmaTech Biologics to create innovative bioconjugate antigen-based vaccines specifically for GSK.